Bellon Steven F. 4

What Happened

• Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics (FHTX), was granted a derivative award on January 30, 2026 to acquire 300,000 shares. The award is recorded at a price of $5.71 per share, totaling $1,713,000 (derivative grant/option).

Key Details

• Transaction date: January 30, 2026; filing date: February 2, 2026 (timely — filed within required 2 business days).
• Grant: 300,000 underlying shares; grant price/strike noted as $5.71; total reported value $1,713,000.
• Post-transaction ownership: Not specified in the Form 4 filing.
• Footnote (vesting): 25% vests on January 30, 2027, then 6.25% of the underlying shares vest on the first day of each calendar quarter thereafter (quarterly vesting after the first anniversary).
• Transaction code: “A” (award/grant); classified as a derivative instrument (option award).

Context

• This was an equity award (option-style grant) rather than an open-market purchase or sale. The award does not represent an immediate cash purchase of shares and does not indicate any immediate sale of shares. Vesting schedule means the economic interest vests over time, subject to future service and other terms in the grant.